Management of graft-versus-host disease in paediatric bone marrow transplant recipients

Paediatric Drugs

Volumn 2, Issue 1, 2000, Pages 29-55

  Zecca, Marco ^a   Locatelli, Franco ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AZATHIOPRINE; CLOFAZIMINE; CORTICOSTEROID; CYCLOSPORIN; ETRETINATE; LYMPHOCYTE ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; PSORALEN; TACROLIMUS; THALIDOMIDE; URSODEOXYCHOLIC ACID;

ACUTE DISEASE; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; GRAFT VERSUS HOST REACTION; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE IRRADIATION; LYMPHOCYTE DEPLETION; PEDIATRICS; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; REVIEW; ULTRAVIOLET RADIATION;

EID: 0033960221     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200002010-00004     Document Type: Review

References (208)

1. 1. Barnes DWH, Loutit JF. Spleen protection: the cellular hypothesis. In: Bacqu ZM, editor. Radiobiology symposium. London: Butterworths, 1955: 134-5
2. 2. Mathé G, Jammet H. Transfusions et greffes de moelle osseuse homologue chez des humains irradiès à haute dause accidentellement, Rév Fr Etudes Clin Biol 1959: 4; 226
3. 3. Ringdén O, Deeg HJ. Clinical spectrum of graft-versus-host disease. In: Ferrara JL, Deeg HJ, Burakoff SJ, editors. Graftvs.-Host Disease. 2nd ed. New York: Marcel Dekker, Inc., 1997: 525-59
4. 4. Barrett J. Graft-versus-host disease. In: Barren J, Treleaven J, editors. Bone marrow transplantation in practice. London: Churchill Livingstone. 1992: 257-72
5. 5. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667-74
6. 6. Antin J, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-8
7. 7. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974 Oct; 18: 295-304
8. 8. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: a retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855-64
9. 9. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-8
10. 10. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980 Aug; 69: 204-17
11. 11. Chao NJ, Deeg HJ. In vivo prevention and treatment of GVHD. In: Ferrara JL, Deeg HJ, Burakoff SJ, editors. Graft-vs.-host disease. 2nd ed. New York: Marcel Dekker, Inc., 1997: 639-66
12. 12. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989 Jan 26; 320: 197-204
13. 13. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program, N Engl J Med 1993 Mar 4; 328: 593-602
14. 14. Eisner MD, August CS. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant 1995 May; 15: 663-8
15. 15. Weisdorf D, Hakke R, Blazar B, et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991 Jun; 51: 1197-203
16. 16. Locatelli F, Uderzo C, Dini G, et al. Graft-versus-host disease in children: the AIEOP-BMT Group experience with cyclosporin A. Bone Marrow Transplant 1993 Dec; 12: 627-33
17. 17. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979 May 10; 300: 1068-73
18. 18. Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981 Jun 18; 304: 1529-33
19. 19. Truitt RL, Johnson BD, McCabe CM, et al. Graft-versus-leukemia. In: Ferrara JL, Deeg HJ, Burakoff SJ, editors. Graft-vs.-Host Disease. 2nd ed. New York: Marcel Dekker, 1997: 385-423
20. 20. Bacigalupo A, van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991 Apr 1; 77: 1423-8
21. 21. Sullivan KM, Storb R, Buckner CD, et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989 Mar 30; 320: 828-34
22. 22. Pession A, Locatelli F, Zecca M, et al. Cyclosporine-A as GVHD prophylaxis in allogeneic BMT for childhood acute leukemia. Bone Marrow Transplant 1998; 21 Suppl. 2: S50-2
23. 23. Locatelli F, Niemeyer C, Angelucci E, et al. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European working group on myelodysplastic syndrome in childhood. J Clin Oncol 1997 Feb; 15:566-73
24. 24. Lazarus HM, Coccia PF, Herzig RH, et al. Incidence of acute graft-versus-host disease with and without methotrexate prophylaxis in allogeneic bone marrow transplant patients. Blood 1984 Jul; 64: 215-20
25. 25. Sullivan KM, Deeg HJ, Sanders J, et al. Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood 1986 Apr; 67: 1172-5
26. 26. Deeg HJ, Storb R, Thomas ED, et al. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 1985 Jun; 65: 1325-34
27. 27. Storb R, Deeg HJ, Thomas ED, et al. Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood 1985 Sep; 66: 698-702
28. 28. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986 Mar 20; 314: 729-35
29. 29. Deeg HJ. Prophylaxis and treatment of acute graft-versus-host disease: current state, implications of new immunopharmacologic compounds and future strategies to prevent and treat acute GVHD in high-risk patients. Bone Marrow Transplant 1994; 14 Suppl. 4: S56-60
30. 30. Ruutu T, Niederweiser D, Gratwohl A, et al. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplant 1997; 19: 759-64
31. 31. Lazarus HM, Vogelsang GB, Rowe JM. Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG). Bone Marrow Transplant 1997; 19: 577-600
32. 32. Martin P, Kernan NA. T-cell depletion for GVHD prevention in humans. In: Ferrara JL, Deeg HJ, Burakoff SJ, editors. Graft-vs.-host disease, 2nd ed. New York; Marcel Dekker, 1997: 615-37
33. 33. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998 Oct 22; 339: 1186-93
34. 34. Hale G, Zhang M-J, Bunjes D, et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998 Dec 15; 92: 4581-90
35. 35. Hale G, Waldmann H. Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection. Bone Marrow Transplant 1998; 17: 305-8
36. 36. Haanen C, De Witte T, Plas A, et al. Prevention of graft-versus-host disease by lymphocyte depletion of the bone marrow graft with use of counterflow centrifugation. Haematologica 1991 Mar; 76 Suppl 1: 22-8
37. 37. Prentice HG, Blacklock HA, Janossy G, et al. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia. Lancet 1982 Mar 27; 1: 700-3
38. 38. Herve P, Flesch M, Cahn JY, et al. Removal of marrow T cells with OKT3-OKT11 monoclonal antibodies and complement to prevent acute graft-versus-host disease. A pilot study in ten patients. Transplantation 1985 Feb; 39: 138-43
39. 39. Mitsuyasu RT, Champlin RE, Gale RP, et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease: a prospective, randomized, double-blind trial. Ann Intern Med 1986 Jul; 105: 20-6
40. 40. Filipovich AH, Vallera DA, Youle RJ, et al. Ex-vivo treatment of donor bone marrow with anti-T-cell immunotoxins for prevention of graft-versus-host disease, Lancet 1984 Mar 3; 1: 469-72
41. 41. Antin JH, Bierer BE, Smith BR, et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies, Blood 1991 Oct 15; 78: 2139-49
42. 42. Champlin RE, Ho W, Gajewski J, et al. Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1990 Jul 15; 76: 418-23
43. 43. Kernan NA, Collins NH, Juliano L, et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986 Sep; 68: 770-3
44. 44. Atkinson K, Farrelly H, Cooley M, et al. Human marrow T cell dose correlates with severity of subsequent acute graft-versus-host disease. Bone Marrow Transplant 1987 Jun; 2: 51-7
45. 45. Martin PJ, Hansen JA, Torok-Storb B, et al. Graft failure in patients receiving T cell-depleted HLA-idenlical allogeneic marrow transplants. Bone Marrow Transplant 1988 Sep; 3: 445-56
46. 46. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991 Oct 15; 78: 2120-30
47. 47. Maraninchi D, Gluckman E, Blaise D, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 1987 Jul 25; 11: 175-8
48. 48. Keever CA, Small TN, Flomenberg N, et al. Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood 1989 Apr; 73: 1340-50
49. 49. Shapiro RS, McClain K, Frizzera G, et al. Epslein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988 May; 71: 1234-43
50. 50. Hale G, Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 1998 Apr 15; 91: 3079-83
51. 51. Wagner JE, King R, Kollman C, et al. Unrelated donor bone marrow transplantation (UBMT) in 5075 patients with malignant and non-malignant disorders: impact of marrow T-cell depletion (TCD) [abstract]. Blood 1998; 92 Suppl. 1: 686a
52. 52. Oakhill A, Pamphilon DH, Potter MN, et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol 1996 Sep; 94: 574-8
53. 53. Hongeng S, Krance RA, Bowman LC, et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet 1997 Sep 13; 350: 767-71
54. 54. Blazar BR, Korngold R, Vallera DA. Recent advances in graft-versus-host disease (GVHD) prevention. Immunol Rev 1997 Jun; 157: 79-109
55. 55. Boussiotis VA, Freeman GJ, Gribben JG, et al. The role of B7-1/B7-2: CD28/CTLA-4 pathways in the prevention of anergy, induction of productive immunity and downregulation of the immune response. Immunol Rev 1996; 153: 5-26
56. 56. Gribben JG, Guinan EC, Boussiotis VA, et al. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Blood 1996 Jun 1; 87: 4887-93
57. 57. Comoli P, Montagna D, Moretta A, et al. Alloantigen-induced human lymphocytes rendered nonresponsive by a combination of anti-CD80 monoclonal antibodies and cyclosporin-A suppress mixed lymphocyte reaction in vitro. J Immunol 1995 Dec; 155: 5506-11
58. 58. Montagna D, Yvon E, Calcaterra V, et al. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor pp55 chain immunotoxin does not impair in vitro anti-leukemia and anti-viral activity. Blood 1999 May 15; 93: 3550-7
59. 59. Cavazzana-Calvo M, Stephan JL, Sarnacki S, et al. Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination. Blood 1994 Jan 1: 83: 288-98
60. 60. Diasio RB, Lo Buglio AF. Immunomodulators: immunosup-pressive agents and immunostimulants. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1291-308
61. 61. Irle C, Deeg HJ, Buckner CD, et al. Marrow transplantation for leukemia following fractionated total body irradiation: a comparative trial of methotrexate and cyclosporine. Leuk Res 1985; 9: 1255-61
62. 62. Storb R, Deeg HJ, Fisher L, et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 1988 Feb; 71: 293-8
63. 63. Storb R, Martin P, Deeg HJ, et al. Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia [letter]. Blood 1992 Jun 1; 79: 3091-2
64. 64. Locatelli F, Zecca M, Romdelli R, et al. Graft-versus-host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood 2000: In press
65. 65. Jolivet J, Cowan KH, Curt GA, et al. The pharmacology and clinical use of methotrexate. N Engl J Med 1983 Nov 3; 309: 1094-104
66. 66. Santos GW, Owens AH. Production of graft-versus-host disease in the rat and its treatment with cytotoxic agents. Nature 1966; 210: 139-40
67. 67. Storb R, Epstein JB, Graham TC, et al. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 1970; 9: 240-6
68. 68. Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977 Apr; 49: 511-33
69. 69. Nevill TJ, Tirgan MH, Deeg HJ, et al. Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1992 May; 9: 349-54
70. 70. Backman L, Ringdén O, Tollemar J, et al. An increased risk of relapse in cyclosporin-treated compared with methotrexate-treated patients: long-term follow-up of a randomized trial, Bone Marrow Transplant 1988 Sep; 3: 463-71
71. 71. Barrett AJ, Horowitz MM, Gale RP, et al. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood 1989 Aug 1; 74: 862-71
72. 72. Storb R, Deeg HJ, Farewell V, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986 Jul; 68: 119-25
73. 73. Tollemar J, Ringdén O, Sundberg B, et al. Decreased incidence of graft-versus-host disease in bone marrow transplantation recipients treated with a combination of cyclosporine and methotrexate. Transplant Proc 1988 Jun; 20: 494-8
74. 74. Storb R, Sanders JE, Pepe M, et al. Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts [letter]. Blood 1991 Aug 15; 78: 1144-5
75. 75. Storb R, Pepe M, Deeg HJ, et al. Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia [letter]. Blood 1992 Jul 15; 80: 560-1
76. 76. Storb R, Deeg HJ, Whitehead J, et al. Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease. Transplant Proc 1987 Feb; 19: 2608-13
77. 77. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989 May 1; 73: 1729-34
78. 78. Aschan J, Ringden O, Sundberg B, et al. Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukaemic relapse compared to monotherapy. Bone Marrow Transplant 1991; 7: 113-9
79. 79. Ringden O, Horowitz MM, Sondel P, et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993 Feb 15; 81: 1094-101
80. 80. Hunter AE, Bessell EM, Russell NH. Effective prevention of acute GVHD following allogeneic BMT with low leukaemic relapse using methotrexate and therapeutically monitored levels of cyclosporin A. Bone Marrow Transplant 1992; 10: 431-4
81. 81. Stockschlaeder M, Storb R, Pepe M, et al. A pilot study of lowdose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. Br J Haematol 1992 Jan; 80: 49-54
82. 82. Ringden O, Klaesson S, Sundberg B, et al. Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings. Bone Marrow Transplant 1992 Jan; 9: 19-25
83. 83. Storb R, Pepe M, Anasetti C, et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 1990 Sep 1; 76: 1037-45
84. 84. Atkinson K. Biggs J, Concannon A, et al. A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy. Aust NZ J Med 1991 Dec; 21: 850-6
85. 85. Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993 Oct 21; 329: 1225-30
86. 86. Deeg HJ, Lin D, Leisenring W, et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomised trial. Blood 1997; 89: 3880-7
87. 87. Sayer HG, Longton G, Bowden R, et al. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood 1994 Aug 15; 84:1328-32
88. 88. Locatelli F, Percivalle E, Comoli P, et al. Human cytomegalo-virus (HCMV) infection in paediatric patients given allogeneic bone marrow transplantation: role of early antiviral treatment for HCMV antigenaemia on patients' outcome. Br J Haematol 1994; 88: 64-71
89. 89. Storb R, Raff RF, Appelbaum F, et al. FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leucocyte antigen-nonidentical donors. Transplantation 1993; 56: 800-7
90. 90. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998 Oct 1; 92: 2303-14
91. 91. Yu C, Seidel K, Fitzsimmons WE, et al. Glucocorticoids fail to enhance the effect of FK506 and methotrexate in prevention of graft-versus-host disease after HLA-nonidentical, unrelated marrow transplantation. Bone Marrow Transplant 1997 Jul; 20: 137-41
92. 92. Uberti JP, Silver SM, Adams PT, et al. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies. Bone Marrow Transplant 1997 Jun; 19: 1233-8
93. 93. Przepiorka D, Ippoliti C, Khouri I, et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 1996 Dec 1; 88: 4383-9
94. 94. Nash RA, Pineiro LA, Storb R, et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood 1996 Nov 1; 88: 3634-41
95. 95. Fay JW, Wingard JR, Antin JH, et al. FK506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. Blood 1996 Apr 15; 87: 3514-9
96. 96. Nash RA, Etzioni R, Storb R, et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 1995 Jun 15; 85: 3746-53
97. 97. Kanamaru A, Takemoto Y, Kakishita E, et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. Bone Marrow Transplant 1995 Jun; 15: 885-9
98. 98. Koehler MT, Howrie D, Mirro J, et al, FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation. Bone Marrow Transplant 1995 Jun; 15: 893-9
99. 99. Storb R, Gluckman E, Thomas ED, et al. Treatment of established human graft-versus-host disease by antithymocyte globulin. Blood 1974 Jul; 44: 56-75
100. 100. Doney KC, Weiden PL, Storb R, et al. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. Am J Hematol 1981; 11: 1-8
101. 101. Doney KC, Weiden PL, Storb R, et al. Failure of early administration of antithymocyte globulin to lessen graft-versus-host disease in human allogeneic marrow transplant recipients. Transplantation 1981 Feb; 31: 141-3
102. 102. Weiden PL, Doney K, Storb R, et al. Antihuman thymocyte globulin for prophylaxis of graft-versus-host disease: a randomized trial in patients with leukemia treated with HLA-identical sibling marrow grafts. Transplantation 1979 Apr; 27: 227-30
103. 103. Hows J, Downie TR, Bradley BA, et al. Influence of immunosuppressive protocols (ISP) on outcome of unrelated donor transplants [abstract]. Blood 1994; 84 Suppl. 1: 332a
104. 104. Blaise D, Olive D, Hirn M, et al. Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients. Bone Marrow Transplant 1991; 8: 105-11
105. 105. Ferrara J, Marion A, Murphy G, et al. Acute graft-versus-host disease: pathogenesis and prevention with a monoclonal antibody in vivo. Transplant Proc 1987 Feb; 19: 2662-3
106. 106. Herve P, Cahn JY, Flesch M, et al. Successful graft-versus-host disease prevention without graft failure in 32 HLA-identical allogeneic bone marrow transplantations with marrow depleted of T cells by monoclonal antibodies and complement. Blood 1987 Feb; 69: 388-93
107. 107. Anasetti C, Martin PJ, Storb R, et al. Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3. Bone Marrow Transplant 1991 May; 7: 375-81
108. 108. Willemze R, Richel DJ, Falkenburg JH, et al. In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation. Bone Marrow Transplant 1992 Apr; 9: 255-61
109. 109. Ferrant A, Latinne D, Bazin H, et al. Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO-Tact-1. Bone Marrow Transplant 1995 Oct; 16: 577-81
110. 110. Krance R, Heslop HE, Mahmoud H, et al. Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donor. Bone Marrow Transplant 1993; 11: 33-6
111. 111. Hamblin M, Marsh JC, Lawler M, et al. Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors. Bone Marrow Transplant 1996 May; 17: 819-24
112. 112. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990 Oct 15; 76: 1464-72
113. 113. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990 Feb 15; 75: 1024-30
114. 114. van Lint MT, Uderzo C, Locasciulli A, et al, Early treatment of acute graft-versus-host disease with high-or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian group for bone marrow transplantation. Blood 1998 Oct 1; 92: 2288-93
115. 115. Hings IM, Filipovich AH, Miller WJ, et al. Prednisone therapy for acute graft-versus-host disease: short-versus long-term treatment: a prospective randomized trial. Transplantation 1993 Sep; 56: 577-80
116. 116. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991 Apr 15; 77: 1821-8
117. 117. Deeg HJ, Loughran TP, Storb R, et al. Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. Transplantation 1985 Aug; 40: 162-6
118. 118. Dugan MJ, DeFor TE, Steinbuch M, et al. ATG plus corticosteroid therapy for acute graft-versus-host disease: predictors of response and survival. Ann Hematol 1997 Jul; 75: 41-6
119. 119. Ohashi Y, Minegishi M, Fujie H, et al. Successful treatment of steroid-resistant severe acute GVHD with 24-h continuous infusion of FK506. Bone Marrow Transplant 1997 Mar; 19: 625-7
120. 120. Gratama JW, Jansen J, Lipovich RA, et al. Treatment of acute graft-versus-host disease with monoclonal antibody OKT3. Clinical results and effect on circulating T lymphocytes. Transplantation 1984 Nov; 38: 469-74
121. 121. Anasetti C, Martin PJ, Storb R, et al. Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. Transplantation 1992 Nov; 54: 844-51
122. 122. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994 Apr 28; 330: 1185-91
123. 123. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998 Sep 1; 92: 1549-55
124. 124. Heslop HE, Benaim E, Brenner MK, et al. Response of steroid-resistant graft-versus-host disease to lymphoblastoid antibody CBL1. Lancet 1995 Sep 23; 346: 805-6
125. 125. Przepiorka D, Phillips G, Ratanatharathorn V, et al. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood 1998 Dec 1; 92: 4066-71
126. 126. Martin PJ, Nelson BJ, Appelbaum FR, et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1996 Aug 1; 88: 824-30
127. 127. Herve P, Wijdenes J, Bergerat JP, et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood 1990 Feb 15; 75: 1017-23
128. 128. Cuthbert RJG, Phillips GL, Barnett MJ, et al. Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy. Bone Marrow Transplant 1992; 10: 451-5
129. 129. Cahn JY, Bordigoni P, Tiberghien P, et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation 1995 Nov 15; 60: 939-42
130. 130. Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994 Aug 15; 84: 1320-7
131. 131. Herve P, Flesch M, Tiberghien P, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992 Jun 15; 79: 3362-8
132. 132. Racadot E, Milpied N, Bordigoni P, et al. Sequential use of three monoclonal antibodies in glucocorticoid-resistant acute GVHD: a multicentric pilot study including 15 patients. Bone Marrow Transplant 1995; 15: 669-77
133. 133. McCarthy Jr PL, Williams L, Harris-Bacile M, et al. A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease. Transplantation 1996 Sep 15; 62: 626-31
134. 134. Besnier DP, Chabannes D, Mahe B, et al. Treatment of graft-versus-host disease by extracorporeal photochemotherapy: a pilot study. Transplantation 1997 Jul 15; 64: 49-54
135. 135. Greinix HT, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 998 Nov 1; 92: 3098-104
136. 136. Sullivan KM, Weiden PL, Starb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989 May 1; 73: 1720-8
137. 137. Zikos P, van Lint MT, Lamparelli T, et al. Allogeneic hematopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: favorable impact of chronic graft-versus-host disease on survival and relapse. Haematologica 1998 Dec; 83: 896-903
138. 138. Doney K, Fisher LD, Appelbaum FR, et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant 1991 Jun; 7: 453-9
139. 139. Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983 Apr; 98: 461-6
140. 140. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combined immunosuppression. Blood 1981; 57: 267-73
141. 141. Atkinson KA. Chronic graft-versus-host disease: review. Bone Marrow Transplant 1990; 5: 69-82
142. 142. Faulds D, Goa KL, Benfield P. Cydosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993; 45: 953-1040
143. 143. Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988 Aug; 72: 546-54
144. 144. Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 1988 Aug; 72: 555-61
145. 145. Deeg HJ, Socié G, Schoch G, et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996 Jan 1; 87: 386-92
146. 146. Fields EO, Gibbs JE, Tucker DF, et al. Effect of thalidomide on the graft versus host reaction. Naturel 1966 Sep 19; 211: 1308-9
147. 147. Wood PM, Proctor SJ. The potential use of thalidomide in the therapy of graft-versus-host disease: a review of clinical and laboratory information. Leuk Res 1990; 14: 395-9
148. 148. Keenan RJ, Eiras G, Burckart GJ, et al. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. Transplantation 1991 Nov; 52: 908-10
149. 149. Neubert R, Nogueira AC, Neubert D. Thalidomide derivatives and the immune system. I. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood. Arch Toxicol 1993; 67: 1-17
150. 150. Neubert R, Nogueira AC, Neubert D. Thalidomide and the immune system. 2. Changes in receptors on blood cells of a healthy volunteer. Life Sci 1992; 51: 2107-16
151. 151. Nogueira AC, Neubert R, Helge H, et al. Thalidomide and the immune system. 3. Simultaneous up-and down-regulation of different integrin receptors on human white blood cells. Life Sci 1994; 55: 77-92
152. 152. Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993 Jun 1; 177: 1675-80
153. 133. Parker PM, Chao NJ, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995 Nov 1; 86: 3604-9
154. 154. Cole CH, Rogers PC, Pritchard S, et al. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. Bone Marrow Transplant 1994 Dec; 14: 937-42
155. 155. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992 Apr 16; 326: 1055-8
156. 156. Heney D, Norfolk DR, Wheeldon J, et al. Thalidomide treatment for chronic graft-versus-host disease, Br J Haematol 1991 May; 78: 23-7
157. 157. Rovelli A, Arrigo C, Nesi F, et al. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplant 1998 Mar; 21: 577-81
158. 158. Chao NJ, Parker PM, Niland JC, et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant 1996 May; 2: 86-92
159. 159. Ochonisky S, Verroust J, Bastuji-Gairn S, et al. Thalidomide neuropathy incidence and clinico-electrophysiological findings in 42 patients. Arch Dermatol 1994; 130: 66-9
160. 160. Leuschner U, Fisher H, Kurlz W, et al. Ursodeoxycholic acid in primary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989; 97: 1268-74
161. 161. Poupon RE, Balkau B, Eschwège E, et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324: 1548-54
162. 162. Chazouillères O, Poupon R, Capron JP, et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 1991; 11: 120-3
163. 163. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998 Oct 22; 339: 1217-27
164. 164. Fried RH, Murakami CS, Fisher LD, et al. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med 1992 Apr 15; 116: 624-9
165. 165. Wulffraat NM, Haddad E, Benkerrou M, et al. Hepatic GVHD after HLA-haploidentical bone marrow transplantation in children with severe combined immunodeficiency: the effect of ursodeoxycholic acid. Br J Haematol 1997 Mar; 96: 776-80
166. 166. Erlinger S. Chronic graft-vs.-host disease of the liver: another indication of ursodeoxycholic acid? Hepatology 1992 Nov; 16: 1305-7
167. 167. Calmus Y, Gane P, Rouger P, et al. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeosycholic acid. Hepatology 1990; 11: 12-5
168. 168. Hymes SR, Morison WL, Farmer ER, et al. Methoxsalen and ultraviolet A radiation in treatment of chronic cutaneous graft-versus-host reaction. J Am Acad Dermatol 1985 Jan; 12: 30-7
169. 169. Jaschonek K, Einsele H, Schmidt H, et al. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Lancet 1988 Mar 12; 1: 599
170. 170. Atkinson K, Weller P, Ryman W, et al. PUVA therapy for drug-resistant graft-versus-host disease. Bone Marrow Transplant 1986; 1: 227-36
171. 171. Eppinger T, Ehninger G, Steinert M, et al. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation 1990 Nov; 50: 807-11
172. 172. Jampel RM, Farmer ER, Vogelsang GB, et al. PUVA therapy for chronic cutaneous graft-vs-host disease. Arch Dermatol 1991 Nov; 127: 1673-8
173. 173. Vogelsang GB, Wolff D, Altomonte V, et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant 1996 Jun; 17: 1061-7
174. 174. Lindelöf B. PUVA and cancer: a large-scale epidemiology study. Lancet 1991; 338: 91-3
175. 175. Simon JC, Tigelaar RE, Bergstresser RP. Ultraviolet B radiation converts Langerhans cells from immunogenic to tolerogenic antigen-presenting cells. J Immunol 1991; 146: 485-91
176. 176. Neuner P, Charvat B, Knobler R. Cytokine release by peripheral blood mononuclear cells is affected by 8-methoxypsoralen plus UV-A. Photochem Photobiol 1994; 59: 182-8
177. 177. Enk AH, Katz SI. Identification and induction of keratinocyte-derived IL-10. J Immunol 1992; 149: 92-5
178. 178. Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. N Engl J Med 1998 Dec 10; 339: 1744-51
179. 179. Owsianowski M, Gollnick H, Siegert W, et al. Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis. Bone Marrow Transplant 1994; 14: 845-8
180. 180. Rossetti F, Zulian F, Dall'Amico R, et al. Extracorporeal photochemotherapy as single therapy for extensive, cutaneous, chronic graft-versus-host disease. Transplantation 1995 Jan 15; 59: 149-51
181. 181. Dall'Amico R, Rossetti F, Zulian F, et al. Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease. Br J Haematol 1997 Jun; 97: 848-54
182. 182. Gerber M, Gmeinhart B. Volc-Platzer B, et al. Complete remission of lichen-planus-like graft-versus-host disease (GVHD) with extracorporeal photochemotherapy (ECP). Bone Marrow Transplant 1997; 19: 517-9
183. 183. Perotti C, Locatelli F, Torretta L, et al. Treatment of drug resistant chronic graft-versus-host disease with a new photoapheresis technique [abstract]. Bone Marrow Transplant 1998; 21 Suppl. 1: S219
184. 184. Perotti C, Torretta L, Viarengo GL, et al. Feasibility and safety of a new technique of extracorporeal photochemotherapy: experience of 240 procedures. Haematologica 1999; 84: 237-41
185. 185. Khavari PA, Edelson R, Linder O. Specific vaccination against photoinactivated cloned T cells [abstract]. Clin Res 1988; 36: 662
186. 186. Dall'Acqua F, Ruzzone B, Guerra B, et al. Unsaturated fatty acids psolarens cycloadducts play a role of second messenger and diacylglycerol. Photochem Photobiol 1994; 59: 55-64
187. 187. Gasparro FP, Dall'Amico R, O'Malley M, et al. Cell membrane DNA: a new target for psolaren pholoadduct formation. Photochem Photobiol 1990; 52: 315-21
188. 188. Aringer A, Graninger WB, Smolen JS, et al. Photopheresis treatment enhances CD95 (FAS) expression in circulating lymphocytes of patients with systemic sclerosis and induces apoptosis. Br J Rheumatol 1997; 36: 1276-82
189. 189. Di Renzo M, Rubegni P, De Aloe G, et al. Extracorporeal photochemotherapy restores Th1/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma. Immunology 1997 Sep; 92: 99-103
190. 190. Socié G, Devergie A, Cosset JM, et al. Low-dose (one gray) total-lymphoid irradiation for extensive, drug-resistant chronic graft-versus-host disease. Transplantation 1990 Mar; 49: 657-8
191. 191. Bullorsky EO, Shanley CM, Stemmelin GR, et al. Total lymphoid irradiation for treatment of drug resistant chronic GVHD. Bone Marrow Transplant 1993 Jan; 11: 75-6
192. 192. Marcellus DC, Altomonte V, Farmer ER, et al. Etrelinate therapy for refractory sclerodermatous chronic graft-versus-host disease. Blood 1999; 93: 66-70
193. 193. Lee SJ, Wegner SA, McGarigle CJ, et al. Treatment of chronic graft-versus-host disease with clofazimine. Blood 1997 Apr 1; 89: 2298-302
194. 194. Schubert MM, Sullivan KM. Recognition, incidence, and management of oral graft-versus-host disease. J Natl Cancer Inst Monogr 1990; 135-43
195. 195. Schubert MM, Sullivan KM, Morton TH, et al. Oral manifestations of chronic graft-v-host disease. Arch Intern Med 1984 Aug; 144: 1591-5
196. 196. Singhal S, Mehta J, Rattenbury H, et al. Oral pilocarpine hydrochloride for the treatment of refractory xerostomia associated with chronic graft-versus-host disease [letter]. Blood 1995 Feb 15; 85: 1147-8
197. 197. Epstein JB, Recce DE. Topical cyclosporin A for treatment of oral chronic graft-versus-host disease. Bone Marrow Transplant 1994 Jan; 13: 81-6
198. 198. Franklin RM, Kenyon KR, Tutschka PJ, et al. Ocular manifestations of graft-vs-host disease. Ophthalmology 1983 Jan; 90: 4-13
199. 199. Murphy PT, Sivakumaran M, Fahy G, et al. Successful use of topical retinoic acid in severe dry eye due to chronic graft-versus-host disease. Bone Marrow Transplant 1996 Sep; 18: 641-2
200. 200. Tseng SC, Maumenee AE, Stark WJ, et al. Topical retinoid treatment for various dry-eye disorders. Ophthalmology 1985 Jun; 92: 717-27
201. 201. Soong HK, Martin NF, Wagoner MD, et al. Topical retinoid therapy for squamous metaplasia of various ocular surface disorders. A multicenter, placebo-controlled double-masked study. Ophthalmology 1988 Oct; 95: 1442-6
202. 202. Atkinson K, Storb R, Prentice RL, et al. Analysis of late infections in 89 long-term survivors of bone marrow transplantation. Blood 1979 Apr; 53: 720-31
203. 203. Atkinson K, Farewell V, Storb R, et al. Analysis of late infections after human bone marrow transplantation: role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease. Blood 1982 Sep; 60: 714-20
204. 204. Noel D, Witherspoon RP, Storb R, et al. Does graft-versus-host disease influence the tempo of immunological recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivors. Blood 1978 Jun; 51: 1087-105
205. 205. Lum LG, Seigneuret MC, Storb RF, et al. In vitro regulation of immunoglobulin synthesis after marrow transplantation. I. T-cell and B-cell deficiency in patients with and without chronic graft-versus-host disease. Blood 1981 Sep; 58: 431-9
206. 206. Witherspoon RP, Storb R, Ochs H, et al. Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood 1981 Aug; 58: 360-8
207. 207. Saxon A, McIntyre RE, Stevens RH, et al. Lymphocyte disfunction in chronic graft-versus-host disease. Blood 1981 Oct; 58: 746-51
208. 208. Tsoi MS, Storb R, Dobbs R, et al. Specific suppressor cells in graft-host tolerance of HLA-idcntical marrow transplantation. Nature 1981 Jul 23; 292: 355-7